Ob/Gyn Medical News about sorafenib; sunitinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma
Journal of Neurosurgery, 09/08/09

Hill KL et al. – The administration of sorafenib and sunitinib in patients with metastatic breast and renal cell carcinoma may lead to reversible clinical and imaging changes following surgical or radiosurgical treatment of their brain lesions. The authors hypothesize that leakage of the drug across a locally impaired blood–brain barrier contributes to peritumoral edema and inflammation, which may be erroneously interpreted as disease progression.

<< Previous
Multiple 18F-FDG-PET/CT for Postoperative Monitoring of Breast...

Next >>
Phytochemical Composition and Antioxidant Capacity of Three...

Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09 Relevance Score: 96%

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety
Hepatology, 11/02/09 Relevance Score: 87%

Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09 Relevance Score: 87%

Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma
Annals of Surgical Oncology, 10/20/09 Relevance Score: 87%

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
European Journal of Endocrinology, 10/06/09 Relevance Score: 87%